Pays: Nouvelle-Zélande
Langue: anglais
Source: Medsafe (Medicines Safety Authority)
Fludarabine phosphate 25 mg/mL;
sanofi-aventis new zealand limited
Fludarabine phosphate 25 mg/mL
50 mg/2mL
Powder for injection
Active: Fludarabine phosphate 25 mg/mL Excipient: Mannitol Sodium hydroxide
Vial, glass, 5 dose units
Prescription
Prescription
Bayer AG
Package - Contents - Shelf Life: Vial, glass, - 5 dose units - 36 months from date of manufacture stored at or below 30°C 24 hours reconstituted stored at 4°C, refrigerate, do not freeze
1991-08-28
Page 1 of 5 FLUDARA ORAL ® (FLU-DA-RA) _Fludarabine phosphate _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about FLUDARA ORAL. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking FLUDARA ORAL against the benefits they expect it will have for you. KEEP THIS LEAFLET. You may need to read it again. WHAT FLUDARA ORAL IS USED FOR This medicine is an anti-cancer drug approved to treat a form of leukaemia known as B-cell chronic lymphocytic leukaemia (B-CLL). This is a cancer of a type of white blood cells called lymphocytes. Patients with B-CLL have too many abnormal white blood cells (lymphocytes) and lymph nodes start to grow in various parts of the body. The abnormal white blood cells cannot carry out their normal disease fighting functions, and may push aside healthy blood cells. This can result in infections, a decreased number of red blood cells (anaemia), bruising and/or bleeding. FLUDARA is a medication that stops the growth of new cancer cells. All cells of the body produce new cells like themselves by dividing. To do this, the cells’ genetic material (DNA) must be copied and reproduced. FLUDARA is taken up by the cancer cells and hinders the production of new DNA. ASK YOU DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed it for another reason. There is not enough information to recommend the use of this medicine for children. BEFORE YOU TAKE FLUDARA ORAL _ _ _ _ _WHEN YOU MUST NOT BE _ _GIVEN IT _ DO NOT HAVE ANY FLUDARA IF YOU HAVE AN ALLERGY TO: • any medicine containing fludarabine • any of the ingredients listed at the end of this leaflet Some of the symptoms of an allergic reaction may include: • shortness of breath • wheezing or difficulty breathing • swelling of the face, lips, tongue or other parts of the body • ras Lire le document complet
flu-ccdsv27-dsv7-14feb23 Page 1 NEW ZEALAND DATA SHEET 1 FLUDARA ® ORAL 10 MG FILM COATED TABLET FLUDARA ORAL 10 mg film coated tablet. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Fludarabine phosphate. FLUDARA ORAL film coated tablets contain 10 mg of fludarabine phosphate. For the full list of excipients, see Section 6.1 3 PHARMACEUTICAL FORM Film coated tablet. FLUDARA ORAL film coated tablets are salmon coloured oval shaped tablets with "LN" indented in a regular hexagon on one side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS FLUDARA ORAL is indicated for the treatment of B-cell chronic lymphocytic leukaemia. 4.2 DOSE AND METHOD OF ADMINISTRATION _DOSE _ _TABLETS FOR ORAL USE _ _Adults _ FLUDARA ORAL tablets should be prescribed by a qualified physician experienced in the use of antineoplastic therapy. The recommended dose is 40 mg fludarabine phosphate/m 2 body surface given daily for 5 consecutive days every 28 days by the oral route. FLUDARA ORAL tablets can be taken either on an empty stomach or together with food. The tablets are to be swallowed whole with water, and must not be chewed or broken. flu-ccdsv27-dsv7-14feb23 Page 2 The duration of treatment depends on the treatment success and the tolerability of the drug. FLUDARA ORAL should be administered up to achievement of best response (complete or partial remission, usually 6 cycles) and then the drug should be discontinued. _TOXICITY _ Dosage may be decreased or delayed based on evidence of haematological and non haematological toxicity. Physicians should consider delaying or discontinuing the drug if toxicity occurs. _IMPAIRED STATE OF HEALTH _ A number of clinical settings may predispose to increased toxicity from FLUDARA ORAL. These include advanced age, renal insufficiency and bone marrow impairment- see Section 4.4, Use in Specialised groups, Impaired state of health. Such patients should be monitored closely for excessive toxicity and the dose modified accordingly. _Impaired renal function _ Dosage reduction is required in renally impa Lire le document complet